Neurocrine and Voyager enter an agreement to fund and develop gene therapy candidates for the treatment of severe neurological diseases.
Neurocrine agrees to pay up to $1.7bn in ... - Cure Parkinson's
Neurocrine agrees to pay up to $1.7bn in gene therapy collaboration
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
3 Replies
•
A very big bet.
they have taken calculated risk. they may have carried out risk analysis before throwing money into it
Not what you're looking for?
You may also like...
MRI Guided Gene Therapy Trial About To Begin at Massachusetts General
To qualify as a candidate for this trial, a PwP must have been diagnosed at least three years ago...
Aromatic L‐Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease
Of the 15 Parkinsons participants in the PD‐1101 clinical trial (evaluating
Gene therapy candidate...
Those with (mostly Ashkenazi) GBA1 gene mutation will be interested to know of gene therapy targeting this.
Research is being done by Prevail Therapeutics in NYC. (I have the mutation and so does my boss's...
Gene therapy is underway!
https://parkinsonsnewstoday.com/2021/02/26/biogen-sangamo-partners-developing-novel-gene-therapies/...
AAV-GAD Gene Therapy
Did anyone hear of AAV-GAD gene therapy? I have a chance to get into a phase 1/2 trial, but...